GPCR Structure Corp: Rasio rega marang prakiraan pendapatan

Structure Therapeutics - logo grafis emiten GPCR

Structure Therapeutics aims to commercialize innovative therapies for metabolic disorders. The development of oral GLP-1 analogs and the success of GSBR-129 create a powerful growth catalyst. The projected P/S ratio reflects these expectations, with the parameter reaching . However, current quotes largely front-run the actual financial impact of the upcoming clinical trials.

Structure Therapeutics Inc. - Rasio kapitalisasi marang dodolan sing dikarepake GPCR (periode 04.07.2022 - 13.11.2026)

Ringkesan rincian data analitis Structure Corp (GPCR)

- rega pasar lan target rega analis:
Bagan rega Structure Therapeutics Inc.|GPCR - Rata-rata rega prakiraan
- data kapitalisasi saham perusahaan:
Nilai pasar Structure Corp|GPCR - Nilai Total Perusahaan
- indikator nilai buku ekuitas:
Nilai Buku saben Saham Structure Therapeutics|GPCR - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku structuretx.com|GPCR - Gunggung Aset Perusahaan
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas Structure Therapeutics|GPCR - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Structure Therapeutics|GPCR - Gunggung kewajiban utang perusahaan|Utang marang nilai buku Structure Corp|GPCR - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Structure Therapeutics|Indikator likuiditas cepet structuretx.com
- rincian asil keuangan lan kelipatan valuasi:
GPCR - Bathi resik|Proyeksi bathi mangsa ngarep Structure Therapeutics|GPCR - Koefisien rega marang bathi|Prakiraan rega marang bathi Structure Pharma|GPCR - Rasio nilai perusahaan marang wutah bathi|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Structure Corp|GPCR - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Structure Therapeutics|GPCR - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan structuretx.com|GPCR - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Structure Therapeutics
- indikator volume dodolan lan pendapatan:
GPCR - Pendapatan dodolan perusahaan|Volume dodolan mangsa ngarep perusahaan Structure Therapeutics Inc.|GPCR - Kapitalisasi marang volume dodolan|Multiplikator Forward P/S Structure Corp
Analisis komprehensif perusahaan:Structure Therapeutics Inc. (GPCR)
Produk asli Structure Therapeutics

Forward P/S is calculated as the ratio of current market capitalization to expected revenue for the next period. This multiple determines the premium paid per unit of future sales, identifying potential undervaluation or an overheated asset. For Structure Therapeutics (GPCR), with a current value of , the metric reflects market expectations for the commercialization of anti-obesity drugs. The trend of the organization's forward P/S allows for an assessment of the business's fair value during the clinical trial stage.

Perusahaan pesaing

Rasio rega marang prakiraan pendapatan Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan NewAmsterdam Pharma N.V. (NAMS)|Multiplikator forward rega marang pendapatan Soleno Therapeutics Corp SLNO|Rasio rega marang prakiraan pendapatan Amicus Therapeutics FOLD|Rasio kapitalisasi marang dodolan sing dikarepake 89bio.com (ETNB)|AGIO: Multiplikator forward rega marang pendapatan|MiMedx Group Inc - Rasio rega marang pendapatan sing dikarepake|Rezolute Corp (RZLT) - Rasio rega marang prakiraan pendapatan|Lexicon Corp - Rega forward marang dodolan|Multiplikator forward rega marang pendapatan MBX|Multiplikator Forward P/S altimmune.com|Multiplikator Forward P/S AARD|Multiplikator forward rega marang pendapatan Sagimet Biosciences, Inc. SGMT|BioAge Labs Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake BMEA (Biomea Fusion Corp)|QNCX: Multiplikator forward rega marang pendapatan|GUTS - Multiplikator Forward P/S|vtvtherapeutics.com (VTVT) - Rasio rega marang prakiraan pendapatan|Agape ATP - Rega forward marang dodolan|PLUR (Pluristem Therapeutics) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Synlogic Corp SYBX|Multiplikator forward rega marang pendapatan LPCN (Lipocine Inc.)|MTNB (matinasbiopharma.com) - Rega forward marang dodolan|Spruce Biosciences, Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake GLTO (Galecto Inc)|Carmell Corp - Multiplikator Forward P/S|Rega forward marang dodolan LUMO (Lumos Therapeutics)|ONVO: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep radiuspharm.com (RDUS)